Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation

详细信息    查看全文

• 作者：Akinobu Takaki (1)
  Takahito Yagi (2)
  Tetsuya Yasunaka (1)
  Hiroshi Sadamori (2)
  Susumu Shinoura (2)
  Yuzo Umeda (2)
  Ryuichi Yoshida (2)
  Daisuke Sato (2)
  Daisuke Nobuoka (2)
  Masashi Utsumi (2)
  Yuko Yasuda (3)
  Eiichi Nakayama (4)
  Yasuhiro Miyake (1)
  Fusao Ikeda (1)
  Hidenori Shiraha (1)
  Kazuhiro Nouso (1)
  Toshiyoshi Fujiwara (2)
  Kazuhide Yamamoto (1)
  
• 关键词：Vaccination ; Living donor liver transplantation ; Hepatitis B immunoglobulin ; Marital donor ; Immune response
• 刊名：Journal of Gastroenterology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：48
• 期：12
• 页码：1373-1383
• 全文大小：
• 作者单位：Akinobu Takaki (1)
  Takahito Yagi (2)
  Tetsuya Yasunaka (1)
  Hiroshi Sadamori (2)
  Susumu Shinoura (2)
  Yuzo Umeda (2)
  Ryuichi Yoshida (2)
  Daisuke Sato (2)
  Daisuke Nobuoka (2)
  Masashi Utsumi (2)
  Yuko Yasuda (3)
  Eiichi Nakayama (4)
  Yasuhiro Miyake (1)
  Fusao Ikeda (1)
  Hidenori Shiraha (1)
  Kazuhiro Nouso (1)
  Toshiyoshi Fujiwara (2)
  Kazuhide Yamamoto (1)
  
  1. Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
  2. Department of Gastroenterological Surgery Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
  3. Okayama University Hospital, 2-5-1 Shikata-cho, Kita-Ku, Okayama, 700-8558, Japan
  4. Kawasaki University of Medical Welfare, 288 Matsushima, Kurashiki, Okayama, 701-0193, Japan
  
• ISSN：1435-5922

文摘

Background A combination of hepatitis B immunoglobulin and nucleos(t)ide analogues is the current standard of care for controlling hepatitis B recurrence after orthotopic liver transplantation (OLT). However, frequent immunoglobulin treatment is expensive and inconvenient. This study investigated the efficacy of hepatitis B virus (HBV) vaccination in preventing the recurrence of hepatitis B after living donor OLT. Methods Twenty-seven patients who had undergone living donor OLT participated in the study; five had acute HBV infected liver failure (ALF-OLT) and 22 had HBV related liver cirrhosis (LC-OLT). Hepatitis B surface antigen (HBsAg)-containing vaccine was administered to them for at least 1year after transplantation and continued once monthly for up to 36months post-OLT. Patients who had anti-HBs antibody titers above 100mIU/mL for a minimum of 6months without immunoglobulin administration were defined as good responders; the others were defined as poor responders. Interferon-enzyme-linked immunospot assays against HBs and HBc antigens were used to assay cellular immune responses. Results All five of the ALF-OLT patients had good responses after a median of four (range 2.5) vaccinations. Nine of the 22 LC-OLT patients had good responses after a median of 19 (range 11.50) vaccinations. Among the LC-OLT group, those with livers donated by relatively higher-aged, marital and high-titer anti-HBs antibody donors were good responders. LC-OLT patients classed as good responders showed interferon-responses comparable to those of the ALF-OLT patients. Conclusions The ALF-OLT and LC-OLT patients who received livers from relatively higher-aged, marital, high-titer anti-HBs antibody donors were the best candidates for HBV vaccine administration. Boosting donors before transplantation may facilitate later vaccine response of the recipients.